UK markets closed

Cosmo Pharmaceuticals N.V. (0RGI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
47.45+1.36 (+2.96%)
At close: 04:19PM BST
Full screen
Previous close46.09
Open46.90
Bid0.00 x 0
Ask0.00 x 0
Day's range46.90 - 47.85
52-week range46.90 - 47.85
Volume377
Avg. volumeN/A
Market cap699.005M
Beta (5Y monthly)1.00
PE ratio (TTM)36.36
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA

    Cosmo Pharmaceuticals N.V. / Key word(s): AGMEGMCosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA 27.05.2022 / 15:15 Press Release (PDF)Dublin, Ireland – 27 May 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) today announced that its shareholders approved all agenda items at today's virtual annual general meeting of shareholders.8,315,019 ordinary shares in the share capital of Cosmo were represented at thi

  • EQS Group

    COSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA

    Cosmo Pharmaceuticals N.V. / Key word(s): MiscellaneousCOSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW(R) TO ALL COUNTRIES EXCEPT CANADA 03.05.2022 / 06:00 Press Release (PDF)Dublin, Ireland - 3 May 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') announces the expansion of the agreement with Medtronic for the distribution of Eleview(R) to all countries except Canada, following the mutual termination of the license agreement with EA Pharma.Eleview(R) is a sub

  • EQS Group

    COSMO ANNOUNCES FULL-YEAR RESULTS 2021;CONFIRMS BEATING GUIDANCE

    Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results23-March-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland - 23 March 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') reports full-year 2021 results for the year ended 31 December 2021, confirms beating guidance, and, as previously announced, proposes a dividend of €0.9